Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Linaprazan glurate - Cinclus Pharma/Jiangsu Sinorda Biomedicine

Next Previous
Drug Profile

Linaprazan glurate - Cinclus Pharma/Jiangsu Sinorda Biomedicine

Alternative Names: SND-001; X-842

Latest Information Update: 13 Jun 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator AstraZeneca
  • Developer Cinclus Pharma; Jiangsu Sinorda Biomedicine Co., Ltd; Shanghai Pharmaceutical Group
  • Class 2 ring heterocyclic compounds; Amines; Aminopyridines; Anti-inflammatories; Antibacterials; Antiulcers; Glutarates; Imidazoles; Pentanoic acids; Pyridines; Small molecules; Toluenes
  • Mechanism of Action Potassium-competitive acid blockers
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Registered Reflux oesophagitis
  • Phase II Duodenal ulcer; Erosive oesophagitis; Helicobacter infections
  • Phase I Gastro-oesophageal reflux

Most Recent Events

  • 22 May 2025 Cinclus Pharma enters into an strategic alliance and licensing agreement with Zentiva to commercialize Linaprazan Glurate in Europe
  • 22 May 2025 Cinclus Pharma plans a phase III trial for Erosive oesophagitis in USA, Europe in Q3 2025
  • 04 Dec 2024 Cinclus Pharma plans to launch linaprazan glurate for Reflux oesophagitis in China (PO) in 2025

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top